News

The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's ...

September 13, 2012 — Janssen Research & Development LLC announced that it has submitted the complete response to the U.S. Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban...

September 7, 2012 — St. Jude Medical Inc. announced results of the FAME II trial demonstrating that patients with...

September 6, 2012 — Daiichi Sankyo Co. Ltd. and Eli Lilly and Co. announced data from the TRILOGY ACS study, a phase III trial comparing prasugrel plus aspirin to clopidogrel plus aspirin in...

August 30, 2012 — Aspirin combined with the antiplatelet drug clopidogrel is no better than aspirin alone for stroke prevention in people with a history of lacunar strokes, and the combination...

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus aspirin. This standard is now being challenged by new agents —...

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially...

August 9, 2012 — The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT study, with the total number of patients randomized...

July 26, 2012 — Transgenomic Inc. has announced that National Government Services, the designated Medicare fiscal intermediary in Connecticut, has confirmed coverage for its proprietary...

July 20, 2012 — Ticagrelor, a blood-thinning drug approved by the U.S. Food and Drug Administration (FDA) in 2011, should be considered along with older blood thinners clopidogrel and prasugrel...

July 20, 2012 — The online clinical drug resource Drugs.com released first quarter 2012 U.S. prescription sales data for the top 100 drugs. Blood thinners, proton-pump inhibitors, antipsychotics...

Over the past decade there have been several advancements in prothrombin time (PT)/international normalized ration (INR) point-of-care testing (POCT) devices. This is usually performed at an...

June 22, 2012 — The the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee voted in May against recommending approval of expanding the indication for...

June 11, 2012 — Boehringer Ingelheim Pharmaceuticals Inc. announced that the Pradaxa (dabigatran etexilate mesylate) capsules prescribing information has been updated to affirm that "Pradaxa 150...

May 23, 2012 — Accumetrics Inc., developer of the VerifyNow System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents,...

The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients...

May 15, 2012 — Reaching out to patients with a few simple phone calls significantly improves the likelihood they’ll continue to take critically important medication that...

April 6, 2012 — The U.S. anticoagulant market is on the verge of a major shift in clinical practice, transitioning from a market dominated by a single injectable anticoagulant to a highly...

March 29, 2012 — Adding vorapaxar, an investigational platelet blocker, to standard antiplatelet therapy significantly reduces the risk of recurrent cardiovascular events in a specific group of...